Shots: The CHMP of EMA approval is based on P-II/III PROTECT VIII trial assessing BAY94-9027 in patients ≥12 years treated previously with severe haemophilia A, (74% receiving BAY94-9027 qw) and (100% receiving BAY94-9027 q5day), evaluating its safety and efficacy P-II/III PROTECT VIII Results: mABR (annualised bleed rate) for qw 0.96; half of them with zero […]Read More
